ImmuCell Corporation announced its unaudited financial results for the year ended December 31, 2025, reporting a 4.3% increase in product sales to $27.6 million and a net loss of $1.0 million, an improvement of $1.1 million compared to the prior year. The results were driven by improved gross margins and manufacturing efficiencies, despite non-recurring charges including a $2.7 million asset write-down.
Key takeaways
Product sales increased 4.3% to approximately $27.6 million for the year ended December 31, 2025.
Net loss improved to $1.0 million, or ($0.12) per basic share, compared to a net loss of $2.2 million, or ($0.26) per basic share, in 2024.
Gross profit margin improved to 41.4% of product sales in 2025, up from 30% in 2024.
Net operating income was $1.6 million for 2025, an increase of $3.3 million compared to 2024.
The Company recorded a $2.7 million write-down of Re-Tain® assets and $651,000 of colostrum inventory write-downs in 2025.
Cash and cash equivalents remained at $3.8 million as of December 31, 2025, with no draw on the $1 million line of credit.